Ruxolitinib and heart failure outcomes among patients with myelofibrosis - PubMed
3 days ago
- #Heart Failure
- #Myelofibrosis
- #Ruxolitinib
- Myelofibrosis (MF) is a myeloproliferative neoplasm with risks of heart failure (HF) and pulmonary hypertension (PH).
- Ruxolitinib is used to palliate symptoms in MF, but its impact on HF hospitalization or new PH was previously unknown.
- A retrospective study of 144 MF patients (31.9% on ruxolitinib) showed ruxolitinib was associated with a lower risk of HF hospitalization or new PH (adjusted subhazard ratio 0.27).
- Ruxolitinib did not significantly affect all-cause death (adjusted HR 0.85).
- Prospective, randomized studies are needed to confirm ruxolitinib's impact on cardiovascular outcomes in MF patients.